Acadia pharmaceuticals inc. (ACAD)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities
Net loss

-235,259

-245,192

-289,403

-271,393

-164,443

-92,475

-37,948

-20,849

-22,765

15,139

-45,145

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

82,265

81,564

75,532

55,265

40,194

16,039

5,711

1,930

1,598

1,583

2,134

Amortization of premiums and accretion of discounts on investment securities

3,613

578

291

-89

2,060

-484

-1,528

133

-105

117

-

Amortization of intangible assets

1,500

1,500

1,500

985

0

-

-

-

-

-

-

Loss on strategic investment

997

-1,840

-

-

-

-

-

-

-

-

-

Depreciation

1,300

1,500

1,200

843

647

206

79

-

-

607

1,111

Income tax benefit from exercise of stock options

-

-

-

596

247

-

-

-

-

-

-

Loss on disposal of assets

-3

-88

-4

-5

-

-

10

252

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

109

285

-

-

Other

-

-

-

-

-

-

-

-

-

-

-323

Amortization of investment premium/discount

-

-

-

-

-

-

-

-

-

-

-260

Non-cash charge resulting from lease termination

-

-

-

-

-

-

-

-

806

-

-

Gain on sales of property and equipment

-

-

-

-

-

-

-

-

-

94

-

Changes in operating assets and liabilities:
Accounts receivable, net

9,691

8,747

11,440

5,903

-

-

-

-

-

-

-

Interest and other receivables

394

612

-150

-401

674

214

505

-279

-

-

-

Inventory

1,737

-1,926

1,012

3,305

-

-

-

-

-

-

-

Prepaid expenses

-2,121

12,270

911

4,731

804

-652

1,484

-41

131

-671

-1,013

Operating lease right-of-use assets

-3,875

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

375

-

-

-

-

-

-

Other assets

-39

236

-431

456

42

108

179

-14

-106

-26

-47

Accounts payable

4,055

-5,619

4,874

2,240

-344

1,644

-1,003

-585

-29

-990

656

Accrued liabilities

6,458

15,994

4,206

15,579

6,256

7,266

2,413

635

277

-2,135

-2,282

Deferred revenue

-

-

-2,644

2,644

-

-55

-379

-2,822

-57

-25,303

28,178

Operating lease liabilities

-2,518

-

-

-

-

-

-

-

-

-

-

Long-term liabilities

1,497

1,367

34

-75

97

127

8

-

-92

-90

-22

Net cash used in operating activities

-151,130

-167,470

-217,757

-208,408

-121,795

-66,434

-31,769

-21,633

-19,897

-10,703

-13,727

Cash flows from investing activities
Purchases of investment securities

578,634

327,914

478,818

683,355

269,486

335,361

211,585

56,728

48,066

54,674

50,265

Maturities of investment securities

413,927

261,678

572,103

430,937

419,197

248,268

86,087

30,948

54,049

53,486

59,750

Purchases of strategic investments

-

3,149

-

-

-

-

-

-

-

-

-

Intangible assets

-

-

-

8,000

-

-

-

-

-

-

-

Proceeds from sale of property and equipment

-

44

-

-

-

-

12

252

-

-128

-41

Purchases of property and equipment

1,129

2,148

812

1,506

2,141

180

618

-

3

-

-

Net cash provided by investing activities

-165,836

-71,489

92,473

-261,924

147,570

-87,273

-126,104

-25,528

5,980

-1,060

9,444

Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs

371,847

306,647

31,188

518,896

14,547

203,851

111,682

98,204

14,022

823

1,923

Proceeds from settlement agreement

-

-

-

14,320

-

-

-

-

-

-

-

Deferred offering costs

-

-

-

-

292

-

-

-

-

-

-

Income tax benefit from exercise of stock options

-

-

-

596

247

-

-

-

-

-

-

Repayments of long-term debt

-

-

-

-

-

-

-

32

78

353

762

Net cash provided by financing activities

371,847

306,647

31,188

533,812

14,502

203,851

111,682

98,172

13,944

470

1,161

Effect of exchange rate changes on cash

2

3

-6

2

7

3

-1

-1

13

20

73

Net decrease in cash, cash equivalents and restricted cash

54,883

67,691

-94,102

63,482

40,284

50,147

-46,192

51,010

40

-11,273

-3,049

Supplemental disclosure of cash flow information:
Cash paid for income taxes

1,597

1,261

1,367

-365

415

-

-

-

-

-

-

Supplemental disclosure of noncash information:
Property and equipment purchases in accounts payable and accrued liabilities

34

160

9

220

156

-

-

-

-

-

-

Stock-based compensation capitalized in inventory

-

-

-

870

-

-

-

-

-

-

-

Unrealized gain (loss) on investment securities

-

-

-

-

-

-

-

-

9

-

-

Interest paid

-

-

-

-

-

-

-

-

-

-

96